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The United Network for Organ Sharing (UNOS) recently revised its
heart allocationpolicy to addressnumerous shortcomingsof thepre-
vious system. Implemented in 2018, the changes sought to reduce
waiting list mortality, clearly define urgency status based on objec-
tive physiologic variables, decrease exemption requests, and intro-
duce geographic modifications to ensure organ distribution favors
the highest urgency candidates. In large part, UNOS policy revisions
were driven by the growing use of continuous low le t ventricular
assist devices (CF-LVADs) and the relevant device complications that
led to an unacceptably high number of status exemptions. The new
6-tiered system assigns a comparatively lower urgency status to pa-
tients supported on CF-LVADs and higher urgency to patients sup-
ported on short-termmechanical circulatory assist (MCA) such as ex-
tracorporealmembraneoxygenation (ECMO)and intraaorticballoon
pump (IABP) counterpulsation. LVAD use as bridge to transplant
(BTT) therapy increased steadily throughout the preceding decade
due to technological improvements and increased physician famil-
iarity, but the recent policy changes introduce incentives for physi-
cians to withhold this life-saving therapy in order to achieve higher
urgency status for their patients. This paper will explore the techno-
logical evolutionofMCAand thepertinent clinical trials that have led
to their FDA approval as BTT and destination therapy. A review of
the inception and development of the donor allocation system will
be provided before examining available post-policy outcome data.
Finally, we will highlight successes and shortcomings of the imple-
mented changes before commenting on areas to potentially expand
upon the existing policy.
Keywords
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1. Introduction
End-stage Heart failure is a devastating clinical syndrome
whose prevalence and incidence continue to grow. The cur-
rent global prevalence of heart failure is estimated at 64 mil-
lion people, accounting for 9.91 million years-lived-with-
disability (YLDs) [1]. Although some patients can be man-
aged with pharmacologic therapy alone, cardiac transplant
remains the gold standard treatment for patients with per-
sistent symptoms despite optimum medical therapy, with an
average survival of 50% at 13 years [2]. However, an insuf-
ficient supply of donor hearts persists despite numerous in-
terventions aimed at expanding the available donor pool and
has resulted inmore time spent on waiting lists and increased
attention toward optimizing management strategies for can-
didates [3]. After results from the REMATCH trial estab-
lished pulsatile-pump mechanical circulatory assist (MCA)
as effective bridge to transplant (BTT) therapy [4], various
forms ofMCAwere developed and used for short-termman-
agement of candidates awaiting transplant. However, with
the advent of continuous flow pumps, advancements in de-
vice durability, and improvements in physician understand-
ing of commercially available technologies, transplant candi-
dates can now be adequately managed for much longer time
periods and non-transplant candidates offeredMCA as desti-
nation therapy [5]. One-year survival for patients supported
on third generation left ventricular assist devices (LVADs)
is over 80%, and historically devastating complications such
as pump thrombosis and pump failure are now scarce events
[6].
Device improvements have contributed to a restructuring
of the United Network for Organ Sharing (UNOS) alloca-
tion system for cardiac grafts [7]. Implemented in October
2018, the changes sought to decrease mortality rates for re-
cipients on the waiting list and introduce additional stratifi-
cationmeasures to clearly define the new 6-tiered system and
its guidelines. Among other priority changes, the restructur-
ing assigns a higher status to patients supported with extra-
corporeal membrane oxygenation (ECMO) and nondischar-
gable temporary MCS. Stable patients on continuous flow-
left ventricle assist devices (CF-LVAD) are assigned a com-
paratively lower urgency status, and patients experiencing
CF-LVAD complications are required to meet a more rigid
set of criteria to attain a higher priority status. Responses to
the implemented changes have been mixed, and early clini-
cal data suggest there may be significant costs associated with
the new stratification metrics [8]. Teuteberg et al. note that
the revisions may unfairly limit the availability of allografts
to patients supported on CF-LAVD [9], and Cogswell et al.
have reported that although allocation restructuring may be
reducing waiting list mortality as intended, post-transplant
outcomes may be worse [10]. Missing from the present lit-
Table 1. NHLBI - National Heart Lung and Blood Institute [2]
1963 First VAD implantation
1969 First TAH implantation
1972 NHLBI initiates an LVAD program
1975 NHLBI sponsors clinical trials of pneumatic LVADs
1991 First implantation of electrical, portable LVAD
1994 First patient discharged from hospital with portable LVAD
2001 REMATCH trial demonstrates superiority of LVAD over optimal medical therapy in New York Heart Association class IV patients
erature is a review of how developments in LVAD technolo-
gies have paved the way for organ allocation restructuring
and how the implemented priority changes are impacting pa-
tients supported on these devices. The goal of this review is
to provide a comprehensive overview of how LVAD evolu-
tion has shaped changes in organ allocation policy, followed
by an examination of new trends and future directions.
2. Ventricular assist: an evolutionary process
TheMCA landscape has expanded and improved dramat-
ically since its inception almost 75 years ago (Table 1). In
1953, Dr. JohnGibbon used theGibbon-IBMheart-lungma-
chine to support an 18-year-old patient during repair of an
atrial septal defect [11], but it wasn’t used until 1963 that Li-
otta et al. reported the successful implantation of an early
VAD [12]. The primitive device utilized an intracorporeal
pneumatically driven pump using left atrial inflow and tho-
racic aorta outflow. Several years later De-Bakey successfully
implanted a paracorporeal pneumatic LVAD to support a pa-
tient suffering from postoperative left ventricular dysfunc-
tion [13]. In 1970, the National Heart and Lung Institute
implemented a program designed to facilitate VAD develop-
ment, and in 1978 the first patient was successfully bridged to
transplant on ventricular assist [14]. This success paved the
way for developing various pulsatile-pump VADs that were
large, noisy, and significantly less durable than present de-
vices. Among the earliest LVAD iterations were the Nova-
cor LVAS, Thoratec IVAD, which was among the first de-
vices to receive FDA approval as BTT therapy in December
1995 [15], and HeartMate XVE, which was used in the piv-
otal REMATCH trial that established a survival advantage for
patients withNYHA class IV heart failure treatedwith LVAD
over optimal medical therapy [4].
After the REMATCH trial solidified pulsatile pumpVADs
as a new long-term myocardial replacement therapy along-
side cardiac transplant, efforts were focused on overcoming
the limitations of pulsatile volume displacement pumps such
as their large size and limited long-term durability. Contin-
uous flow pumps were studied throughout the early 2000’s,
and numerous technologies became commercially available
including DuraHeart LVAD and MicroMed Debakey VAD.
However, it wasn’t until 2008 when the United States Food
and Drug Administration approved HeartMate II for BTT
therapy after its pivotal clinical trial [16]. This was a prospec-
tive, multicenter study that assessed 133 patients awaiting
cardiac transplant who were inotrope-dependent or sup-
ported with an intra-aortic balloon pump. Patient survival
during the 126 day median treatment period with Heart-
Mate II was 75%, and one year survival was 68%. Patients
supported with HeartMate II also experienced superior qual-
ity of life and improved functional status compared to their
counterparts managed with optimal medical therapy. The
following year, Slaughter et al. published results of a 2-
year, prospective, randomized study comparing the pulsatile-
pump HeartMate XVE to the continuous axial-flow pump
HeartMate II [17]. The primary study endpoints were sur-
vival free from debilitating stroke, reoperation, or device re-
pair. Overall, they reported superior achievement of the pri-
mary study endpoint with the HeartMate II, a greater 2-year
survival rate, and fewer adverse events compared to Heart-
Mate XVE. The results of this study led to HeartMate II
achieving FDAapproval as BTT therapy in January 2010 (Ta-
ble 2). The HeartMate II is a second generation LVAD that
uses an axial-flow continuous-flow pump consisting of a ro-
tor suspended in blood by pivot bearings. Fewer moving
parts and the continuous mechanism contribute to improved
device durability and reduced rates of thrombosis and pump
failure compared to the XVE pulsatile pump.
Two years later results published from the Advanced
Heart Failure Bridge to Transplant trial led to the FDA ap-
proval of HeartWare HVAD as BTT therapy [18]. In this
study, Aaronson et al. compared results of 144 patients await-
ing transplant who were supported with the HVAD contin-
uous flow centrifugal pump to 499 axial-flow pump controls,
predominantly HeartMate II. The primary outcome variable
was overall survival on the originally implanted device, suc-
cessful transplantation, or successful explantation to ventric-
ular recovery after six months. Overall, success was achieved
in 90.7% of HVAD patients and in 90.1% of controls, es-
tablishing noninferiority of HVAD compared to HeartMate
II. The primary difference between the centrifugal and axial
flowpumps lies in the specific design of the rotating elements.
Whereas the axial-flow rotor spins to eject blood in a direc-
tion parallel to the rotating elements, the centrifugal-pump
rotating elements receive and eject blood tangentially from
the blade tips, a mechanism that reduces shear stress, blood
trauma, and thrombosis [19].
In 2017, the Clinical Trial to Evaluate the HeartWare
Ventricular Assist System (ENDURANCE trial) compared
the efficacy of HVAD to HeartMate II as destination ther-
apy [20]. This was a multicenter, randomized trial that com-
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Table 2. AbbreviationMRS, modified Rankin scale
Device Clinical Trial Design Primary Endpoints Seminal Publication
and FDA Approval
HeartMate II BTT BTT Patients, no control arm Survival at 6 mo, noninferiority to expected survival if
65% for BTT patients
2007/2008
HeartMate II DT Randomization of DT patients 2 : 1 for HeartMate II vs
HeartMate XVE
Survival at 2 y, free of disabling stroke (MRS > 3) or
device failure
2010
HVAD BTT Control arm was chosen from INTERMACS registry Noninferior survival at 6 mo 2012
HVAD DT Randomization of DT patients in 2 : 1 for HVAD vs
HeartMate II
Noninferior survival at 2 y free of disabling stroke
(MRS> 4) or device failure
2017
HeartMate 3 BTT Randomization of both BTT and DT patients in 1 : 1
ratio to HeartMate 3 vs HeartMate II
Noninferior survival at 6 mo free of disabling stroke
(MRS> 3) or device failure
2017
HeartMate 3 DT Nested within the same trial as the BTT study Noninferior survival at 2 y free of disabling stroke
(MRS> 3) or device failure
2018
Despite meeting the primary noninferiority endpoint, there was a concern for a higher incidence of stroke in the HVAD group. As a result, the FDAmandated
a supplemental trial that tested efficacy of tight blood pressure control to reduce the incidence of strokes with HVAD. Based on a combination of data from
the original and supplemental trial, the device was then FDA approved for DT2.
pared results of 297 patients treated with HVAD to 148 con-
trols supported with HeartMate II, all of whom were ineli-
gible for transplant. The primary endpoint was survival at
two years free from debilitating stroke or device removal
due to malfunction or failure. The success rates for the two
groups were 55.4% and 59.1%, respectively, with a greater
percentage of controls requiring device replacement (16.2%
vs 8.8%) and a greater percentage of HVAD patients expe-
riencing a stroke (29.6% vs 12.1%). Subsequent analysis of
the ENDURANCE trial identified several variables that could
potentially account for the HVAD stroke association. These
included discrepancies in antiplatelet therapy dosing, pump
design differences, and lower international normalized ratios
(INR) in the study group [21]. The variable that received the
most attention, however, was elevatedmean arterial pressure
(MAP), which was identified as a highly statistically signif-
icant independent risk factor for stroke events in the trial.
This led to the FDA-mandated ENDURANCE supplemental
trial, designed to evaluate the effect of intense blood pressure
control on stroke reduction after one year of HVAD therapy.
Results showed that patients with a MAP below 85 mmHg
experienced a non-significant reduction in stroke rates after
one year compared to results from the original trial (22.3% to
16.9%) [22]. Data published in the supplemental trial com-
bined with original data led to HVAD achieving FDA ap-
proval in 2017 as destination therapy for patients who were
ineligible for cardiac transplant.
Later in 2017, results from theMOMENTUM3 trial com-
paring HeartMate III to HeartMate II were published. Heart-
Mate III was a new, fully magnetically levitated centrifugal
continuous flow pump engineered to carry a lower risk for
pump thrombosis than the traditional axial-flow pump in
HeartMate II [23]. 152 patients supported with HeartMate
III were compared to 142 treated with HeartMate II, and the
primary outcome of interest was a composite of survival free
of disabling stroke at one, three, and six months. The pri-
mary endpoint was achieved in 86.2% in the HeartMate III
group and in 76.8% of theHeartMate II group. Therewere no
significant differences between HM II and HM III in overall
mortality (13.1% vs 15.5%) or rates of disabling stroke (5.9%
vs 3.9%), but reoperation due to pump malfunction occurred
more frequently in the HeartMate II group (14.3% vs 2.7%).
Additionally, no patients in the HeartMate III group expe-
rienced pump thrombosis compared to 14 patients (10.1%)
in the HeartMate II group. This led to the device’s FDA ap-
proval as BTT therapy in 2017 and as destination therapy in
October 2018.
3. Donor allocation: a historical perspective
The allocation of donor hearts inevitably requires the dis-
tribution of a highly coveted and finite resource to candidates
who meet a rather narrow set of selection criteria. The fun-
damental goal of organ allocation policies has always been to
produce methods that allow for equitable access to available
organs while maximizing the overall value of the transplant
[24]. In the 1980’s, the Organ Procurement and Transplan-
tation Network (OPTN) assembled a consortium of cardiolo-
gists and cardiothoracic surgeons called the Heart Transplant
Committee which would become the Thoracic Organ Trans-
plantation Committee. The committee’s stated objectives
were to design andmonitor thoracic organ allocation policies
and to address issues related to procurement and transplan-
tation. Among the committee’s first actions was the approval
of a primary allocation algorithm which utilized a two-tiered
system for medical urgency, status 1 and status 2. Patients
were classified as status 1 if admitted to the ICU and requir-
ing inotropic support or receiving mechanical circulatory as-
sist, including support with ventricular assist, TAH, or IABP.
Status 2 included all other transplant candidates, including
those suffering from refractory angina, congenital heart dis-
ease, refractory ventricular tachycardia, and various restric-
tive cardiomyopathies [8]. Candidates supported on VADs
were assigned status 1 priority due to the poor durability and
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high complication rates of the available devices which in-
cluded thromboembolism, mechanical pump failure, and in-
fection [25]. This policy remained in effect for the following
decade despite criticism that it excluded critically ill adult pa-
tients from status 1 designation, including patients for whom
MCAwas contraindicated and thosewith life-threatening ar-
rythmias [26]. In 1999, the OPTN instituted a major pol-
icy change that stratified status 1 patients into distinct tiers,
1A and 1B. The 1A classification required patients to either
be admitted to the transplant center or to have experienced
a VAD complication within the previous 30 days. Patients
supported by ventricular assist for 30 days without complica-
tion and those requiring inotropes were designated 1B. How-
ever, all patients supported on ventricular assist were as-
signed 1A status for a 30-day period immediately upon de-
vice implantation, irrespective of hemodynamic stability or
candidacy for a different intervention. Among other priori-
ties, the policy change reflected the needs of patients suffer-
ing fromhigh LVADcomplication rates and permitted candi-
dates supported by MCA the opportunity to achieve highest
priority status. The enacted policy reduced median waiting
times for 1A and 1B designated patients compared to pre-
policy status 1 patients, and it reduced overall waiting list
mortality [27]. In 2002, the policy requiring VAD patients
to accrue status 1A time immediately upon device implanta-
tion was dissolved, allowing patients to be listed as 1A dur-
ing any 30-day period following VAD implantation. Patients
were also not required to be hospitalized to maintain 1A sta-
tus designation, allowing for medical optimization prior to
achieving 1A status.
Between 2006 and 2015 the number of cardiac transplants
increased almost 3-fold and the percentage of patients sup-
ported with durable VADs increased from 16% to 36% [28].
In 2018, The United Network of Organ Sharing (UNOS)
made significant revisions to the heart allocation policy in the
United States. Designed to reduce waiting list mortality, the
newly implemented 6-tier system (statuses 1-6) introduced
additional categories to more clearly define the urgency sta-
tus of candidates and address perceived shortcomings of the
previous 3-tiered system [8]. Specifically, the modifications
sought to correct the following: an excessive number of can-
didateswithin 1A suffering from a broad spectrumof urgency
needs, inconsistencies in the geographic sharing scheme, and,
crucially, a lack of accounting for the increasing use and dura-
bility of MCS devices and relevant complications.
Prior to the implemented changes, patients in cardiogenic
shock supported with ECMO and stable patients experienc-
ing ventricular assist complications were all assigned 1A sta-
tus and competed equally for organs. This led to concern
for overcrowding within the highest urgency status and per-
ceived inequities in organ allocation. Some of the strongest
evidence given in support of the policy change was the sig-
nificant variance in six month waiting list mortality rates
among different status 1A candidates: 4.8% among patients
with MCS infection, 5.1% for candidates supported on ven-
tricular assist for 30 days, and 35.7% for those supported on
ECMO. Patients supported on mechanical ventilation and
ECMO experienced the highest waiting list mortality among
status 1A candidates, and VAD-supported candidates utiliz-
ing their discretionary 30-day status and thosewith infections
had the lowest waiting list mortalities [29]. Other candidates
poorly served by the previous system included patients with
congenital heart disease and patients intolerant of inotropic
medication or suffering from potentially fatal arrythmias: be-
tween 2009 and 2011, these candidates together comprised
nearly all of the 605 status 1A exemptions that were submit-
ted, with over 90% receiving approval.
In response, the allocation systemwas redesigned to strat-
ify previously status 1A patients into three tiers (1, 2 and
3) with different urgency statuses (Table 3). Candidates as-
signed the highest priority status were those in cardiogenic
shock and supported with ECMO or another biventricular
non-dischargeable MCS, as well as those supported on MCS
with a life-threatening arrythmia. Patients supported on
LVAD, IABP, MCAwith device malfunction, and those with
potentially fatal ventricular arrythmias not requiring MCA
were all assigned status 2. Patients supportedwith LVADand
using their discretionary 30 dayswere assigned status 3, along
with those experiencing device infection, pump thrombosis,
and hemolysis. This status 2 and 3 designations for various
patient populations on LVAD therapy reflect the technical
and clinical improvements made to devices and the percep-
tion that patients supported on them have less urgent needs
than previously. They were also driven by the expanding use
of LVADs and the device complications that resulted in an
excessive number of high priority status exemptions. Stud-
ies analyzing early results of the allocation change shed light
on the clinical impact already made and provide information
about the changing landscape to guide physicians and inform
patients.
4. Clinical outcomes
The OPTN recently published results of the impact the
new policy has had on the types of mechanical device support
used, waiting listmortality, and post-transplant survival [30].
They report an overall increase in patients supported with
short-termMCA therapies such as ECMO (3.7% to 6.5%) and
IABP (12% to 27%) and a decrease in LVADuse (79% to 61%).
These results are consistent with those reported by Cogswell
et al. who observed a significant decrease in the patients
bridged to transplant on LVAD therapy, a 4-fold increase in
transplant recipients supported by ECMO, and overall longer
ischemic time (3.0 to 3.4 hours) [10]. The OPTN report
found that the number of deaths per 100 patient years was
highest in Status 1, followed by Status 2 then Status 3, which
was interpreted as indicative of the policy’s improvements in
risk-stratifying candidates. This observation was also made
by Goff et al., who compared transplant characteristics and
early outcomes between the old and new systems [8]. They
found a 10% increase (68% to 78%) in transplants given to the
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• Non-dischargeable Ventricular Assist Device2
•MVS with life threatening arrhythmia2
2
• Non-dischargeable LVAD2
• Intraaortic Balloon Pump2
• Dischargeable TAH/RVAD/BiVAD2
•Mechanical circulatory support with mechanical failure2
• VF/VT without mechanical circulatory support2
3
• Dischargeable LVAD3
• High Dose inotrope/ multiple inotropes requiring monitoring2
• ECMO4
• Non-dischargeable LVAD5
• Intraaortic Balloon Pump5
• Percutaneous Endovascular LVAD5
• Mechanical Circulatory Support with Right Ventricular failure2, infection6, aortic






• Inotropes without monitoring8
• Intractable angina8
• Congenital heart disease8
• Re-transplant8
5 •Multiple organ transplant9
2 6 • All others9
1 Renewable every 7 days
2 Renewable every 14 days
3 Discretionary 30-day period
4 If status 1 is not renewed
5 If status 2 is not renewed
6 14 days if clinical evidence of driveline infection, 42 days if bacteremia requiring antibiotic, 90 days if device pocket
infection or recurrent bacteremia
7 14 days if two hospitalizations in 6 months, 90 days if 3 times in past 6 months
8 Renewable every 90 days
9 180 days
highest urgency patients (previously status 1A and presently
statuses 1-3) and reported that six-month post-transplant pa-
tient survival was not significantly different between the two
eras (93.6% pre and 92.8% post). Although no difference was
observed for waiting list mortality between the two groups
(14.8 pre to 14.9 post deaths per-100 patient years), waiting
list mortality for status 1 candidates aligned with Scientific
Registry of Transplant Recipients (SRTR) modeling and was
significantly higher than lower status candidates (statuses 2-
6). The higher waiting list mortality observed in the greatest
urgency status was interpreted as clinically meaningful evi-
dence of improved stratification with the new system, a find-
ing consistent with the OPTN report.
The OPTN report also found that 77% of post-policy
transplant recipients were distributed between status 1 (8%),
status 2 (46%), and status 3 (23%), as opposed to 68% of pre-
policy transplants occurring in 1A and 28% in 1B. They ob-
served no change in one-year waiting list mortality or six-
month graft survival, results that differ from those reported
by Cogswell et al., who found that 90-day and 180-day sur-
vival estimates were lower in the new system compared to
the old (87.5% and 94.5%; 77.9% and 93.4%). Cogswell et al.
also reported that six-month waiting list survival was higher
in the new system compared to the previous (96.1% to 95.0%)
but concluded that the modest reduction in waiting list mor-
tality likely does not compensate for the observed worse out-
comes, especially considering the waiting list mortality in the
previous system was already low.
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The newpolicy does not appear to reduce exemptions, nor
does it address the incentive for physicians to initiate orwith-
hold LVAD therapy to achieve a higher urgency for patients.
UNOS proposed that the introduction of additional stratifi-
cation metrics and more clearly defined hemodynamic list-
ing requirements would reduce the number of exemption re-
quests but likely lead to an overuse of high-priority support
therapies like ECMO and IABP. Results from Parker et al.
are consistent with fears of short-term therapy overuse but
suggest the policy change may actually be increasing exemp-
tions, particularly within the status 2 group [31]. Their anal-
ysis compares baseline characteristics and clinical outcomes
of pre and post-policy cohorts and demonstrates a significant
increase in patients supported on IABP (4.5% to 8.2%) and
ECMO (1.2% to 2.6%), and a decrease in LVAD therapy (27%
to 24%). Exemptions increased significantly (3.5% to 15%)
and both low-dose and high-dose inotrope therapy declined
(23% to 5.6% : 8.8% to 5.8%).
5. Present challenges and future research
These reports raise interesting and complex issues about
the paradigm shift taking place as a result of the allocation re-
structuring. The decline in patients supported with durable
LVAD and rise in ECMO and IABP use suggest clinical de-
cision making may be prioritizing status urgency at the ex-
pense of medical optimization. Patients who may be best
served with LVAD therapy could be discouraged or prohib-
ited from therapeutic options because of the comparatively
lower urgency status it confers, and a disproportionately large
number of patients offered higher-urgency temporary ther-
apies such as ECMO. This trend forces patients to compete
for organs based on clinical deterioration and creates incen-
tives for physicians to withhold potentially life-saving treat-
ment, a scenario akin to withholding dialysis treatment for a
renal transplant candidate in clinical decline to optimize the
candidate’s likelihood of being matched to a donor [32]. In
this scenario, the “life-boat” problem acknowledged with the
previous system [33] will continue to burden transplant cen-
ters with more high-urgency candidates who are not being
optimally managed, worsening patient outcomes and organ
survival.
The policy changes also appear to be having early and pro-
found effects onmedian time spent on transplantwaiting lists
and on the number of patients listed and delisted for trans-
plantation. Although median waitlist times appear to be de-
creasing among the highest urgency candidates, preoperative
hospital staysmay be increasing, leading to a resource shift to-
ward intensive inpatient management strategies that can be
costly for transplant centers and fail to serve the best inter-
ests of patients [34]. Whether or not the policy changes are
impacting the total number of patients listed for transplant
remains unanswered, but considering the observed trends to
date, it appears likely that total listing will rise alongside in-
creases in use of MCS devices that confer a higher priority
status such IABP and ECMO.
The new allocation system also fails to sufficiently address
multiorgan transplant; patients receiving simultaneous heart
and kidney transplants experience a significantly higherwait-
ing list mortality compared to heart transplantation alone,
and the new policy does not address the urgency needs of
this patient population [35]. Assigning status 1 designation
to multiorgan transplant candidates would theoretically re-
duce the multiorgan waiting list mortality without introduc-
ing significant costs on the lifeboat. Amendments to the
newest allocation system will also need to address the effect
of therapeutic provider discretion on patient chances of re-
ceiving a transplantation. Lung allocation score (LAS) and
Model for end-stage liver disease (MELD) score have proved
invaluable tools for stratifying lung and liver transplant can-
didates [36, 37], respectively, but attempts to create a similar
objective set of criteria for cardiac transplantation have either
proved to be ineffective or have failed to address patients sup-
ported on MCS. Creating a comprehensive and valid patient
stratification tool is a crucial step toward improving alloca-
tion policies and optimizing the net benefit of every donor.
Although extensive research has been undertaken to identify
negative predictors of long-term graft function and patient
quality of life [38], these findings have failed to translate into
an effective set of patient stratification metrics. Lastly, the
regional variation in donor availability and disparate waiting
list time for candidates in different geographic regions remain
poorly understood and insufficiently addressed by the imple-
mented changes, limiting the conclusions that can be drawn
from available studies.
6. Conclusions
Improvements in device design and durability have led to
an increasing number of cardiac transplant candidates being
managed with some form of MCA, in particular LVADs. In
large part, the reorganization ofUNOS allocation criteriawas
driven by the growing number of candidates bridged to trans-
plant on continuous-flow LVADs. The lower urgency status
assigned to patients supported by LVAD compared to ECMO
has resulted in a smaller percentage of LVAD patients ul-
timately bridged to transplant and a substantial increase in
ECMO-supported patients who receive donor grafts. Con-
sistent with its intended goals, the policy shift has introduced
additional stratification metrics to prioritize the highest ur-
gency patients and more clearly defined guide listing criteria.
To date there has not been a significant reduction in waiting
list mortality, although this goal may ultimately be achieved
as more time passes since initial policy implementation. Al-
though the total volume of cardiac transplants has remained
the same since allocation restructuring, there may be more
patients being placed on devices that afford them higher pri-
ority status. Understanding the full effect of the policy change
on long-term graft performance and overall mortalitywill re-
quire a longer period of observation and additional research
investments. Nevertheless, it is clear that allocation prior-
ity policy changes have a substantial impact on patients sup-
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portedwith continuous-flowLVADs, and patients can expect
additional policy changes as the commercially available device
landscape expands and improves.
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